Novo Nordisk is to acquire Cardior Pharmaceuticals for up to €1.025 billion Euros, including an upfront payment and additional payments if certain development and...
US biotechnology company Neomorph signed a $1.46 billion licensing agreement with Novo Nordisk to discover, develop and commercialize molecular glue degraders.
Novo Holdings, Novo Nordisk's parent company, is acquiring US contract development and manufacturing organization (CDMO) Catalent for $16.5 billion. The companies said...
Novo Nordisk wants to make another major capital investment in production capacity for its diabetes and obesity therapies. The Danish drugmaker announced to spend more...
Danish drugmaker Novo Nordisk plans to invest more than 42 billion Danish kroner (about €5.6 billion) starting in 2023 to expand existing manufacturing facilities at the...
Novo Nordisk has agreed to acquire ocedurenone for uncontrolled hypertension with potential application in cardiovascular and kidney disease from KBP Biosciences for up...
Novo Holdings, controlling shareholder in drugmaker Novo Nordisk, and healthcare investment firm Gurnet Point closed their acquisition of US antibiotics specialist...
Danish drugmaker Novo Nordisk has agreed to acquire Montreal, Canada-based Inversago Pharma. The transaction is worth up to $1.075 billion in cash if certain development...
